Prudential Financial
ACRS icon

Prudential Financial’s Aclaris Therapeutics ACRS Stock Holding History

Prudential Financial’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107K Buy
20,270
+6,890
+51% +$30.7K ﹤0.01% 2331
2026
Q1 		$50.2K Buy
+13,380
New +$45.1K ﹤0.01% 2315
2019
Q2 		– Sell
-27,410
Closed -$164K – 2453
2019
Q1 		$164K Buy
27,410
+557
+2% +$3.69K ﹤0.01% 2338
2018
Q4 		$198K Buy
+26,853
New +$277K ﹤0.01% 2250

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Prudential Financial's ACRS Position: Q2 2026 in Review

Prudential Financial increased its Aclaris Therapeutics (ACRS) stake by 51% in Q2 2026, buying an estimated $30.7K and bringing the position to 20,270 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #2331.

Prudential Financial first reported a position in ACRS in Q4 2018 and has held it in 4 quarters since. The position peaked at $198K in Q4 2018. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Prudential Financial held 20,270 shares of Aclaris Therapeutics worth $107K as of Q2 2026.
  • Prudential Financial bought 6,890 Aclaris Therapeutics shares in Q2 2026, an estimated $30.7K.
  • Aclaris Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2331 holding.
  • Prudential Financial first reported a position in Aclaris Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Prudential Financial's Aclaris Therapeutics position peaked at $198K in Q4 2018.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.